Health Care·Biotechnology·$2.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.50 | N/A | -20.48% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.50 | N/A | -20.48% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for future performance.
The company is focused on advancing its clinical programs despite the current financial results.
Celldex Therapeutics reported a larger-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. The stock's decline reflects market reaction to the disappointing earnings results and uncertainty ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EOG RES INC
Nov 3, 2008